Elios Therapeutics
Blood & Organ Banks · South Carolina, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
111 Smith Hines Rd Ste E, Greenville, So...Website
www.eliostherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 2
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
2
2
3
2
2
About Elios Therapeutics
Elios Therapeutics specializes in personalized therapeutic cancer vaccines, focusing on patients with solid tumors. Founded in 2014, the company leverages innovative transgenic technology developed by Dr. Thomas Wagner to create autologous vaccines that enhance the immune system's ability to target and destroy tumor cells. Their lead product, the Tumor Lysate, Particle Only (TLPO) vaccine, aims to provide a safe and effective immunotherapy option for patients, particularly those at high risk of melanoma recurrence. Elios Therapeutics is committed to advancing cancer treatment through personalized medicine and ongoing clinical trials.Explore more
Elios Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Elios Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Elios Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Elios Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Elios Therapeutics
Click to see if Elios Therapeutics had a recent Job posting/layoffs
Elios Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Elios Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Elios Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Elios Therapeutics is spiking on competitors!
Recommended Actions
Find VP level buyers at Elios Therapeutics
Find 2 more new buyers
Compare Similar Companies to Elios Therapeutics
Compare insights from companies similar to Elios Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Elios Therapeutics is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Elios Therapeutics is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Elios Therapeutics.
Elios Therapeutics Tech Stack
A closer look at the technologies used by Elios Therapeutics
See more technologies
Elios Therapeutics News & Media
Elios Therapeutics Strengthens Board of Directors with Appointment of Key Financial Executive Michael Caprio
AUSTIN, Texas, Sept. 29, 2021 /PRNewswire/ -- Elios Therapeutics, LLC, an immuno-oncology company focused on the development and commercialization of next-generation, immune-mediated technologies for the treatment of cancer, today announced the appointment of Michael Caprio, C.P.A., an...Elios Therapeutics Personalized Cancer Vaccine Demonstrates Long-Term Survival Benefit Among High-Risk Melanoma Patients in Phase IIb Final Analysis
AUSTIN, Texas, Aug. 5, 2020 /PRNewswire/ -- Elios Therapeutics, a biopharmaceutical company developing innovative personalized therapeutic cancer vaccines, today announced final data from a prospective, randomized, double-blind, placebo-controlled Phase IIb clinical trial evaluating...Elios Therapeutics Presents New Phase IIb Data for Personalized Cancer Vaccine in High-Risk Melanoma Patients at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium
AUSTIN, Texas, Feb. 7, 2020 /PRNewswire/ -- Elios Therapeutics, a biopharmaceutical company developing innovative personalized therapeutic cancer vaccines, today announced that the Company presented a subgroup analysis of the prospective, randomized, double-blind, placebo-controlled Phase...Elios Therapeutics Presents New Phase IIb Data for Personalized Cancer Vaccine in High-Risk Melanoma Patients at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Elios Therapeutics, a biopharmaceutical company developing innovative personalized therapeutic cancer vaccines, today announced that the Company presented a subgroup analysis of the prospective, randomized, double-blind, placebo-controlled Phase IIb clinical trial evaluating its personalized tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine, in patients with Stage III and IV resected melanoma.
Read more news
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Elios Therapeutics
Sign Up For FreeTo access detailed company insights
Elios Therapeutics specializes in personalized therapeutic cancer vaccines, focusing on patients with solid tumors. Founded in 2014, the company leverages innovative transgenic technology developed by Dr. Thomas Wagner to create autologous vaccines that enhance the immune system's ability to target and destroy tumor cells. Their lead product, the T... Read More
